This is a prospective study designed to determine the toxicity, efficacy and antileukemic effect of high-dose cytosine arabinoside (ara-C), cyclophosphamide and total body irradiation (TBI) as a myeloablative regimen prior to allogeneic bone marrow transplantation for patients with hematologic malignancies. Fifty-eight patients with hematologic malignancies were treated with cyclophosphamide, high-dose ara-C and total body irradiation (TBI) followed by allogeneic bone marrow transplantation. Fifty patients had good prognosis disease and eight had poor prognosis disease. Cyclosporine and short-course methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. The conditioning regimen consisted of ara-C 3000 mg/m 2 twice a day × six doses on days −7, −6, and −5; cyclophosphamide 1800 mg/m 2 on days −4 and −3; and TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions administered twice a day on days −4, −3, −2, and −1. The bone marrow was infused on day 0 (zero). Toxicity related to the conditioning regimen was comparable to that reported with other conditioning regimens, except for diarrhea which appears to be more frequent. The actuarial survival at 1 year was 69% (58-82) and at 5 years was 54% (42-69) with the numbers in parentheses representing the 95% confidence interval of the KaplanMeier estimate. After a median follow-up of 28 months, 31 of 58 (53%) patients are alive without evidence of disease. Only four of the 58 patients (7%) have relapsed. Cyclophosphamide, ara-C and TBI is a safe and effective myeloablative regimen for patients with leukemia. The overall relapse rate in our study was 7% with a median follow-up of 28 months and appears to be lower than relapse rates reported in other series. This is probably due to the added antileukemic effect of ara-C. This regimen should be compared with other myeloablative regimens in a controlled study.
transplant; myeloablation; preparative regimen; venoocclusive disease; leukemia Bone marrow transplantation is an effective treatment modality for patients with a variety of hematologic malignancies. 1 The cure rate for acute non-lymphocytic leukemia (ANLL) in first complete remission (CR1), 2 and chronic myelogenous leukemia (CML) in stable phase 3 is about 50%. For high risk acute lymphocytic leukemia (ALL) in first complete remission it is 40-60%. 4 In spite of receiving a myeloablative regimen, consisting of chemotherapy and radiation a good proportion of patients relapse. For AML in CR1 the relapse rate is 15-25%. 5, 6 For ALL in CR1 the relapse rate is 30%, 7 and for CML patients in stable phase the morphologic relapse rate is about 10-20%. [8] [9] [10] For patients with AML in CR2 and beyond, the relapse rate is 50-75%, 6, 11 and CML in accelerated phase and blast phase the relapse rate is as high as 30-70%. 12 In ALL patients in CR2 and beyond, the relapse rate is 50-60%. 13, 14 In the past, various cytotoxic agents have been used as preparation for allogeneic transplantation to reduce the incidence of relapse. They have included combinations such as cyclophosphamide, TBI; busulfan, cyclophosphamide; 8 high-dose ara-C and TBI; 15 high-dose etoposide and TBI; 16 high-dose cyclophosphamide, BCNU and VP-16 (CBV); 17 and etoposide, cyclophosphamide and TBI. 18 Leukemic relapse still remains an important cause of treatment failure in transplanted patients. Cytosine arabinoside is an effective antileukemic agent and has been found to be very useful in the treatment of primary leukemias as well as refactory lymphomas and leukemias. [19] [20] [21] The purpose of this study was to determine if the addition of high-dose ara-C to cyclophosphamide and TBI was feasible and if it enhanced the antileukemic effect of the conditioning regimen.
Materials and methods

Eligibility criteria
The protocol was submitted to the Human Investigation Committee and was approved. Patients with a confirmed diagnosis of ALL, ANLL, CML, and myelodysplastic syn-drome were included in the study. Acute lymphocytic leukemia patients in second or subsequent remission, or adults and poor prognosis patients in first remission; ANLL patients in first or subsequent remission; CML patients in stable or accelerated phase and myelodysplastic syndrome patients were eligible for transplantation. A related HLAidentical donor, a related donor with a single HLA-antigen mismatch or an unrelated HLA-identical donor was available. Matched unrelated donor transplants were initiated in August 1992.
Exclusion criteria
The presence of active viral, fungal or bacterial infections; cardiac, pulmonary, hepatic and renal function of less than 80% of predicted value; HIV infection, CML in blast crisis and ALL and ANLL in full relapse were criteria for exclusion.
Patients
Fifty-eight patients were treated at the Yale Bone Marrow Transplant Unit from January 1989 to January 1995 (Table  1) . Twenty patients were in AML-CR1, three AML-CR2, one AML-CR3, 19 CML stable phase, four CML accelerated phase, one ALL CR1, four ALL-CR2, two ALL-CR3 and others four. The age range was 0-20, 20 patients; 21-40, 27 patients and greater than 41, 11 patients. Fifty patients had good prognosis disease and eight had poor prognosis disease (Table 2) .
Transplant regimen
The myeloablative regimen consisted of cytosine arabinoside 3000 mg/m 2 twice a day × six doses on days −7, −6, and −5; cyclophosphamide 1800 mg/m 2 on days −4 and −3; TBI 1400 cGy midline dose at 5 cGy/min in eight total fractions twice a day on days −4, −3, −2 and −1. Bone marrow was infused on day 0 (zero). GVHD prophylaxis consisted of methotrexate 10 mg/m 2 i.v. on days +1, +3, +6 and +11. Cyclosporine 1.5 mg/kg i.v. every 12 h on days +1 to +14 or until the patient was able to take it orally; and then 6.25 mg/kg orally every 12 h until day +100 followed by a 5% decrease per week.
Bone marrow harvest
Bone marrow was harvested from the anterior and posterior iliac crests via multiple bone marrow punctures as previously described. 22 The cell dose was 1-3 × 10 8 nucleated cells/kg recipient body weight. The marrow was infused through a central venous catheter.
Supportive therapy
All patients were placed in clean, high-efficiency particulate air (HEPA) filtered rooms with laminar air flow and were treated in strict isolation. Gastrointestinal decontamination was with gentamycin, vancomycin and nystatin. Broad-spectrum intravenous antibiotics were given if patients developed fever and were neutropenic. Appropriate antibiotics were continued if patients had documented viral, fungal or bacterial infections. Continuous bladder irrigation was administered during cyclophosphamide therapy. Irradiated, CMV negative packed red blood cell transfusions were given to maintain the hemoglobin greater than 8.0 g/dl and platelet transfusions were given to maintain the platelet count greater than 20 × 10 9 /l. None of the patients received colony-stimulating factors.
Trimethoprim/sulfamethoxazole was started after complete engraftment and continued to +12 months post-transplant for Pneumocystis carinii prophylaxis. After November 1992 patients considered to be at high risk for hepatic veno-occlusive disease 23 were placed on heparin prophylaxis at 100 units/kg/24 h continuous infusion from day −7 to day +30. This included patients greater than age 30, patients who had received extensive prior therapy and patients with a prior history of hepatitis and abnormal liver function tests. Prophylactic intravenous gamma-globulin at 200 mg/kg was given every 3 weeks for the first 100 days and then monthly for the first year. Patients considered at high risk for significant GVHD received intravenous gamma-globulin 400 mg/kg weekly for the first 100 days and then intravenous gamma-globulin 200 mg/kg monthly for the first year. All patients who received matched unrelated transplants were given anti-thymocyte globulin (ATG) at 10 mg/kg on days −6, −4 and −2 as part of the preparative regimen. Significant acute graft-versus-host disease was treated with anti-thymocyte globulin and/or high-dose corticosteroids. A dietary consultation was obtained for all patients and hyper-alimentation was initiated at the recommendation of the dietician.
Evaluation of engraftment
Engraftment was evaluated by daily blood counts. Neutrophils were considered engrafted on the day the ANC was greater than 0.5 × 10 9 /l. Platelets were considered engrafted when the count was greater than 50 × 10 9 /l independent of transfusions. A bone marrow aspirate, biopsy and confirmative cytogenetic studies were done on day +28 post- 
Analysis
Results were analyzed by diagnosis, and patients were categorized as good risk and poor risk. Additional covariates included age and donor type. Disease-free survival and overall survival were compared using parametric (exponential, Weibull), nonparametric (Kaplan-Meier) and semiparametric (proportional hazard) methods in SAS and Splus.
Results
Patient characteristics
Fifty-eight patients were enrolled into the study from January 1989 to January 1995. Thirty-four were male and 24 were female. Age range at the time of transplantation was 2 to 58 years (median age 30). Forty patients received matched related transplants, five received related partially mismatched transplants, two received syngeneic transplants and 11 received matched unrelated transplants.
Engraftment
The range for WBC engraftment was 15-31 days (median 23 days) and for platelet engraftment 12-154 days (median 26 days). Two patients did not achieve granulocyte and platelet engraftment and four patients did not achieve complete platelet engraftment and had a prolonged count of less than 50 000.
Early toxicity
A thorough assessment of the regimen-related toxicity was undertaken. Early toxicity (up to 30 days post-transplant) related to the conditioning regimen was graded based on the regimen-related toxicity grading system 24 (Table 3) . GI toxicity as a result of the conditioning regimen was common. Grade I nausea was seen in 22%, grade II in 59% and grade III in 14% of the patients; grade I vomiting was seen in 19%, grade II in 55% and grade III in 23% of the patients; grade I oral mucositis was seen in 41%, and grade Table 3 Non-hematologic toxicity (n = 58) Nausea, vomiting and cerebellar toxicity are not graded in the regimenrelated toxicity grading system. 24 II in 53% of the patients; grade I diarrhea was seen in 71% and grade II in 28%. Patients were treated with standard antiemetics, morphine and anti-diarrheals. Hyper-alimentation was used in 57/58 patients and the median duration of TPN requirement was 38 days. Grade I bladder toxicity was seen in 17 patients (29%) in the form of hematuria, which lasted from 2 to 15 days. All 17 patients were treated with bladder hydration with resolution of symptoms. Ara-C-related cerebellar complications were seen in eight patients (14%). In five patients, the symptoms were mild and consisted of either headache or nystagmus or both. Three patients had a severe reaction, which manifested as ataxia, dysarthria and cognitive dysfunction. One of the three patients with severe reactions had a seizure, which required treatment with phenobarbital for 2 weeks, but the seizures were not persistent. A second patient did not receive three doses of ara-C due to severe cerebellar toxicity. Eye complications consisted of mild conjunctivitis in eight patients that did not require treatment; two developed moderate conjunctivitis requiring topical eye drops and one patient developed corneal erosion that required antibiotics and an eye patch.
GVHD
Thirty-four patients developed acute GVHD; 11 had grade I, 19 had grade II, three had grade III and one had grade IV. Thirteen patients had chronic GVHD with persistent symptoms requiring prolonged immunosuppressive ther-apy. Three patients died of complications related to chronic GVH.
VOD
Twenty-one patients had VOD; it was mild in 15 patients with a peak bilirubin of less than 5; moderate in two patients with a peak bilirubin between 5 and 10 and severe in four patients with a peak bilirubin of greater than 10. Four patients died of complications related to VOD. Twenty-five patients who were felt to be at high risk for VOD received heparin prophylaxis. Of the 25 high-risk patients who received heparin, three had severe VOD, one moderate, eight mild and 13 none. Of the 33 who did not receive heparin prophylaxis, nine patients had VOD; seven mild, one moderate and one severe.
Other complications
A total of 15 patients (26%) developed pulmonary complications. Twelve developed complications early, (Ͻ1 year) and three after 1 year. Eight patients had idiopathic pneumonia and seven documented infections. Twelve of the 15 patients who developed lung complications died. Five of the deaths were due to idiopathic pneumonia and seven had documented infections. Four of the infections were due to CMV, one CMV and PCP, one RSV and one aspergillus. Three of the patients with lung complications are alive. Three patients aged 39, 50 and 52 with no prior cardiac history, developed atrial fibrillation (grade II cardiac toxicity). Two of the three patients died of treatment-related toxicity and a third patient responded to anti-arrhythmic therapy and is alive. One patient aged 3 at transplant with a prior history of anthracycline use (pre-transplant ejection fraction not available) developed congestive heart failure with a low ejection fraction (grade II toxicity), etiology of which is uncertain, and continues to require inotropic and after-load reducing therapy.
Relapse
Of the 58 patients, four patients relapsed (7%) at a median follow-up of 28 months (Table 4 ). Two of the relapsed patients were poor risk patients of a total of eight poor risk patients. One patient had CML in accelerated phase and the other was a patient with ALL in CR3 who relapsed in the donor cells. The other two relapses were AML in CR. None of the patients who received matched unrelated transplants relapsed. All four of the relapsed patients died. 
Survival
Of the 58 patients who have been transplanted, 31 (53%) are alive and 27 (47%) had died (Figures 1 and 2 ) at a median follow-up of 28 months (range 16-88 months). Eight patients died in the immediate post-transplant period (days 25-97) due to treatment-related complications. None of them were discharged from the transplant unit. The causes included: Candida sepsis (one), VOD (four), acute graft-versus-host disease (one) and mixed etiology (two). Twelve patients died of respiratory complications; eight of the deaths were due to lung complications that occurred before 1 year and four were after 1 year. Three patients died of chronic GVH. Four patients died of relapse and the time of relapse was from 6-24 months.
Survival by transplant type is as follows. Twenty-four of the 42 (57%) matched related patients, three of five (60%) related partially mismatched patients and four of 11 (36%) matched unrelated patients are alive with a median followup of 28 months. With the same duration of follow-up, two of the eight (25%) poor prognosis patients and 29 of the 50 (58%) good prognosis patients are alive. 
Discussion
The primary purpose of the study was to determine the feasibility of adding high-dose ara-C to cyclophosphamide and TBI as a myeloablative regimen. The other goal was to evaluate the complication profile and the long-term antileukemic effect of the combination. Our study shows that allogeneic bone marrow transplantation using this regimen is an effective treatment modality for leukemias. Fifty-three percent of our patients are alive with a median follow-up of 28 months. In the good prognosis patients, survival is 58% with a follow-up of 28 months.
GI toxicity was quite common in our series. Grade II and III nausea and vomiting were seen in less than 75% of patients. This was no higher than what has been reported with other regimens such as busulphan/cyclophosphamide 25 and cyclophosphamide/TBI. 24 Grade II stomatitis was seen in less than 50% of patients and again this was similar to other regimens such as bulsulfan/cyclophosphamide, 26, 27 and cyclophosphamide and TBI. 24 Grade II diarrhea was seen in 28% of patients and this was higher than has been reported with regimens such as busulfan and cyclophosphamide. 26 However, it was no more frequent than what has been reported with radiation containing regimens such as cyclophosphamide and TBI. In addition, 57/58 patients received total parental nutrition (TPN). The median duration of TPN requirement was 38 days (range 14-102). TPN was initiated at the recommendation of the dietician and continued until the oral intake improved and the prealbumin and albumin levels were in the normal range. This was meticulously observed in all patients resulting in the prolonged duration of TPN. We do not feel the prolonged TPN use was due to the GI toxicity of ara-C.
Cerebellar toxicity in our series related to ara-C was seen in eight patients, but was significant in three patients. Full doses of ara-C were not given to one patient as early severe cerebellar toxicity developed, which resulted in withholding three doses. In all of the eight patients, symptoms resolved after completion of the ara-C. Eye complications occurred in 11 patients and in the surviving patients there were no residual symptoms. Cerebellar and eye complications are unique to this regimen, but were self-limiting.
Interstitial pneumonitis was seen in 15 of the 58 (26%) patients transplanted. Seven of the patients had definite documentation of infection and all of them died of respiratory failure. Eight patients had idiopathic interstitial pneumonitis and five of these patients died of respiratory failure. Three patients are alive and their quality of life is good with no respiratory compromise. Acute ARDS is a known complication of ara-C and is thought to be due to a capillary leak syndrome. 28 In all our patients, respiratory symptoms occurred after day 30. This suggests that none of the respiratory complications were due to this mechanism. The occurrence is probably due to a combination of chemotherapy/radiotherapy and is no more frequent than the incidence with other conditioning regimens such as cyclophosphamide and TBI (33%), 1 cyclophosphamide and busulfan (12%), 25 and cyclophosphamide, VP-16 and TBI (20%). 18 Four of 58 (7%) patients transplanted in our study relapsed. Two of these patients had poor prognosis disease and two had good prognosis disease. Our conditioning regimen compares very well with the other conditioning regimens that have been used in the past such as cyclophosphamide TBI (relapse rate of 30%), busulfan, cyclophosphamide 25 (relapse rate of 12%); TBI and etoposide 16 (relapse rate of 30%) and etoposide, cyclophosphamide and TBI 18 (relapse rate of 33%). The combination of cyclophosphamide, ara-C and TBI has been studied in the past and two reports have been identified. One series 29 used ara-C and TBI with and without cyclophosphamide. A total of 29 patients mostly beyond CR1 were treated. This study demonstrated that it was feasible to administer high-dose ara-C in combination with TBI and cyclophosphamide but no definitive conclusions could be made due to the small number of patients studied. A second study 30 reported 84 patients treated with a lower dose of ara-C in combination with TBI and cyclophosphamide and showed a relapse rate of approximately 10%. This further supports the idea of added anti-leukemic effect of ara-C.
High-dose ara-C, cyclophosphamide and TBI is an effective myeloablative regimen. Cerebellar and eye complications are unique to this regimen, but are self-limiting. GI toxicity, specifically diarrhea, appears to be more frequent. A good anti-leukemic effect resulted with a low relapse rate, which appears superior to that reported with other regimens. It should be prospectively compared to other myeloablative regimens in a controlled study.
